Thorough understanding of the HO-1-mediated signaling pathways that control membrane-bound CD163 expression will be useful in developing novel therapeutic approaches to treat hemolysis-induced tissue injury in SCD and other hemolytic diseases. The gene discussed is CD163; the disease is Schnyder corneal dystrophy.